Blood Cancer: Medical Treatments

Department of Health and Social Care written question – answered on 1st July 2020.

Alert me about debates like this

Photo of Martyn Day Martyn Day Shadow SNP Spokesperson (Public Health and Primary Care)

To ask the Secretary of State for Health and Social Care, what treatment options are available to patients with multiple myeloma who have become refractory to previous lines of therapy.

Photo of Jo Churchill Jo Churchill The Parliamentary Under-Secretary for Health and Social Care

Holding answer received on 11 June 2020

For patients who have received previous lines of treatment, the National Institute for Health and Care Excellence (NICE) currently recommends the following subsequent treatments in England:

- Daratumumab with bortezomib and dexamethasone (NICE TA573);

- Carfilzomib (NICE TA 457);

- Bortezomib (NICE TA 129); and

- Ixazomib with lenalidomide and dexamethasone (NICE TA505).

For some patients, stem cell transplantation may also be considered, however, the treatment is very intensive and requires a good level of fitness.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.